The Cannasoul Group is a drug discovery company focused on developing groundbreaking therapeutics derived from natural compounds. Founded by world-renowned cannabis researcher and pioneer Prof. Dedi Meiri from the Technion – Israel Institute of Technology and backed by robust scientific capabilities, Cannasoul bridges the gap between botanical medicine and the pharmaceutical industry.
Cannasoul’s proprietary analytical platform, data-driven approach, unique knowhow and clinical trial framework support active compound identification and development, from
botanical extract through clinical approved formulation.
With years of experience in the world of analytical chemistry, we provide support to pharmaceutical companies that are looking for a dedicated and highly professional team that can assist them through the research and development stages of their project.
Equipped with versatile equipment including HPLC, UPLC, LC-MS/MS (Orbitrap), LC-MS/MS (QQQ), GC-MS/MS (QQQ), ICP-MS and more, we support pharmaceutical companies with the widest range of analytical services.
Bioanalytics refers to the analysis of molecules in biological samples. These can be samples from animals or humans, they can be fluid (e.g., plasma, serum, urine, etc.) or solid tissues (Brain, liver, kidney, etc.)
Using state of the art, high-resolution Orbitrap LC-MS/MS, we can detect molecules down to the ppb level.
This exceptional capability is essential in the development of new therapeutic agents, as accurate and reliable data are the basis for critical Go/No Go decisions.
For samples from precious clinical samples, we develop and validate bioanalytical methods under GCLP accreditation, thus ensuring the generation of reliable data that can be used in future development and regulatory submissions.
With extensive expertise in extraction, separation, and isolation technologies, we serve as a unique service lab for extracting specific compounds from botanical matrices.
This includes the isolation of rare or minute compounds for structural determination and the creation of analytical standards.
With our strong bioanalytical abilities, we support the bio analysis of samples from preclinical (non-GLP) and clinical (GCLP) studies.
Using state of the art highly sensitive and reliable equipment (orbitrap LC-MS/MS), advanced analytical capabilities and an expert and dedicated team, our bioanalytical services provide essential support to preclinical and clinical studies, including analytical method development and validation for both APIs or pharmaceuticals.
Cannasoul has a unique expertise in Cannabis analysis and is able to provide an extensive list of support in both batch release services and R&D including:
